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Abstract
Growing evidence indicates that innate immune molecules regulate microglial activa-
tion in Alzheimer's disease (AD); however, their effects on amyloid pathology and
neurodegeneration remain inconclusive. Here, we conditionally deleted one allele of
myd88 gene specifically in microglia in APP/PS1-transgenic mice by 6 months and
analyzed AD-associated pathologies by 9 months. We observed that heterozygous
deletion of myd88 gene in microglia decreased cerebral amyloid β (Aβ) load and
improved cognitive function of AD mice, which was correlated with reduced
number of microglia in the brain and inhibited transcription of inflammatory genes,
for example, tnf-α and il-1β, in both brain tissues and individual microglia. To investi-
gate mechanisms underlying the pathological improvement, we observed that
haploinsufficiency of MyD88 increased microglial recruitment toward Aβ deposits,
which might facilitate Aβ clearance. Microglia with haploinsufficient expression of
MyD88 also increased vasculature in the brain of APP/PS1-transgenic mice, which
was associated with up-regulated transcription of osteopontin and insulin-like growth
factor genes in microglia. Moreover, MyD88-haploinsufficient microglia elevated pro-
tein levels of LRP1 in cerebral capillaries of APP/PS1-transgenic mice. Cell culture
experiments further showed that treatments with interleukin-1β decreased LRP1
expression in pericytes. In summary, haploinsufficiency of MyD88 in microglia at a
late disease stage attenuates pro-inflammatory activation and amyloid pathology,
prevents the impairment of microvasculature and perhaps also protects LRP1-medi-
ated Aβ clearance in the brain of APP/PS1-transgenic mice, all of which improves
neuronal function of AD mice.
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1 | INTRODUCTION
Alzheimer's disease (AD) is a progressive neurodegenerative disease
pathologically characterized by extracellular amyloid β (Aβ) deposits,
intracellular neurofibrillary tangles, and microglial activation (Heneka
et al., 2015). Genome-wide association studies correlated microglial
genes (i.e., TREM2, APOE, CD33, ABCA7, and PLCG2) with the occur-
rence of late-onset AD, which highlights an essential role of microglia in
AD pathogenesis (Lewcock et al., 2020). In AD mouse models, which
overexpress Alzheimer's amyloid precursor protein (APP) in neurons,
microglia are activated and recruited to Aβ deposits (Bolmont
et al., 2008; Meyer-Luehmann et al., 2008), and are more closely corre-
lated with the impairment of cognitive performance than Aβ deposition
(Focke et al., 2018). Elimination of microglia at a late disease stage with
noticeable Aβ already in the brain prevents the synaptic and neuronal
loss in APP-transgenic mice (Spangenberg et al., 2016). However, acti-
vated microglia also exert a protective effect on neurons in AD mice by
up-taking Aβ peptides (Michaud et al., 2013) and promoting degradation
of phosphorylated tau proteins in neurons (Qin et al., 2016).
Many studies through cross-breeding or bone marrow recon-
struction have shown that the innate immune signaling regulates
microglial activation in AD mice. Deficiency of CD14 (Reed-Geaghan,
Reed, Cramer, & Landreth, 2010), Toll-like receptor (TLR) 2 (S. Liu
et al., 2012), TLR4 (Song et al., 2011), myeloid differentiation factor
88 (MyD88) (Hao et al., 2011), interleukin receptor-associated kinase
4 (IRAK4) (Cameron et al., 2012), inhibitor of nuclear factor κ-B kinase
subunit β (IKKβ) (Y. Liu et al., 2014), or NLR family pyrin domain con-
taining 3 (NLRP3) (Heneka et al., 2013) attenuates the degree of
inflammation, shifts inflammatory activation from pro-inflammatory to
anti-inflammatory profiles, or both in the brain of APP-transgenic
mice. However, results on the effects of innate immunity on Aβ
pathology and neuronal degeneration in AD mice are often contradic-
tory. For example, deletion of MyD88 or its downstream signaling
molecule, IRAK4, and IKKβ, or disruption of the interaction between
TLR2 and MyD88, attenuates Aβ pathology and neuronal death in
APP-transgenic mice (Cameron et al., 2012; Hao et al., 2011; Lim
et al., 2011; Y. Liu et al., 2014; Rangasamy et al., 2018), whereas,
wild-type MyD88 was also reported to promote Aβ clearance and
protect neurons (Michaud, Richard, & Rivest, 2011, 2012). There was
one study even showing that overall deletion of MyD88 in AD mice
have no effects on neuroinflammation and Aβ deposition (Weitz,
Gate, Rezai-Zadeh, & Town, 2014). It is difficult to explain the appar-
ently conflicting results delivered from different animal models and
different experimental methods. However, in the investigation of
MyD88 and AD, it should be noted that: (a) MyD88 functions not only
in microglia, but also in other brain cells (e.g., neurons, astrocytes and
endothelial cells; Gosselin & Rivest, 2008; Hung et al., 2018; Shen
et al., 2016); and (b) overall deletion of MyD88 in AD mice alters
development of the brain and is potentially fatal (Michaud
et al., 2011; Schroeder et al., 2021). Thus, to clarify the pathogenic
role of MyD88 in AD, MyD88 expression should be manipulated spe-
cifically in microglia or other brain cells within a designed time win-
dow in AD animals.
Growing evidence suggests that vascular disorders contribute to
AD pathogenesis. AD patients often have vascular pathologies, which
are from large artery atherosclerosis, cerebral amyloid angiopathy
(CAA) to microvascular disease, and blood–brain–barrier (BBB) impair-
ment (Cortes-Canteli & Iadecola, 2020). We observed a reduction of
vasculature and blood flow in the hippocampus of APP- or tau-
transgenic AD mice (Decker et al., 2018). Pericytes wrapping around
endothelial cells are essential for the maintenance of normal structure
and function of cerebral blood circulation, which include BBB homeo-
stasis and angiogenesis (Sweeney, Ayyadurai, & Zlokovic, 2016). Peri-
cytes are injured in AD at an early disease stage (Montagne
et al., 2020; Nation et al., 2019). Deletion of pericytes increases per-
meability of BBB, decreases vasculature and blood flow, and exagger-
ates Aβ accumulation in the brain of APP-transgenic mice (Montagne
et al., 2018; Sagare et al., 2013). BBB is able to efficiently clean cere-
bral Aβ by transporting Aβ outside of brain (Roberts et al., 2014),
which is at least partially mediated by low-density lipoprotein
receptor-related protein 1 (LRP1) and ATP binding cassette subfamily
B member 1 (ABCB1) (Kuhnke et al., 2007; Shinohara, Tachibana,
Kanekiyo, & Bu, 2017). Interestingly, LRP1 also mediates Aβ internali-
zation by pericytes, thereby cleaning Aβ locally at BBB
(Ma et al., 2018). However, how microglia regulate microcirculation,
pericyte function, and BBB-mediated Aβ clearance in AD brain
remains unclear.
In this study, we knocked out one allele of myd88 gene specifi-
cally in microglia in APP/PS1-transgenic mice by 6 months and inves-
tigated amyloid pathology, neuroinflammation, and cerebral
vasculature by 9 months. We observed that haploinsufficiency of
MyD88 in microglia attenuated AD-associated pathologies and
protected neurons.
2 | MATERIALS AND METHODS
2.1 | Animal models and Cross-breeding
APP/PS1-double transgenic mice over-expressing human mutated
APP (KM670/671NL) and PS1 (L166P) under Thy-1 promoters
(Radde et al., 2006) were kindly provided by M. Jucker, Hertie Insti-
tute for Clinical Brain Research, Tübingen, Germany; myd88-floxed
mice (B6.129P2[SJL]-Myd88tm1Defr/J; MyD88fl/fl; Stock number:
008888; Hou, Reizis, & DeFranco, 2008) were imported from the
Jackson Laboratory, Bar Harbor, ME; and Cx3Cr1-CreERT2 mice that
express a fusion protein of Cre recombinase and an estrogen receptor
ligand binding domain under the control of endogenous cx3cr1 pro-
moter/enhancer elements (Goldmann et al., 2013) were kindly pro-
vided by M. Prinz, University of Freiburg, Germany.
APP/PS1-transgenic mice were cross-bred with MyD88fl/fl and
Cx3Cr1-Cre mice to obtain mice with the following genotypes: APPtg
or wtMyD88fl/wtCre+/− and APPtg or wtMyD88fl/wtCre−/−. In order to
minimize potential toxic effects of MyD88 deficiency on the
physiological function, we used heterozygous myd88-floxed mice
(MyD88fl/wt) in the whole study. To induce the recombination of
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myd88 gene, 6-month-old mice were injected (i.p.) with tamoxifen
(Sigma-Aldrich Chemie GmbH, Munich, Germany; 100 mg/kg) in corn
oil once a day over 5 days. The phenotype of APP/PS1-transgenic
mice with or without haploinsufficient expression of MyD88 in
microglia was compared between siblings. As a control experiment,
APP/PS1-transgenic and Cx3Cr1-Cre mice were mated with gpr43-
floxed mice (Tang et al., 2015) to obtain mice with APPtgGpr43fl/
flCre+/− and APPtgGpr43fl/flCre−/− of genotypes. Control mice were
treated completely the same as for MyD88-deficient mice. To identify
cells, which express Gpr43, Gpr43-RFP reporter mice overexpressing
monomeric red fluorescence protein (mRFP) under the control of
gpr43 promoter (Tang et al., 2015) were used. Both gpr43-floxed mice
and Gpr43-RFP reporter mice were kindly provided by S. Offermanns,
Max Planck Institute for Heart and Lung Research, Germany. All ani-
mal experiments were performed in accordance with relevant national
rules and authorized by Landesamt für Verbraucherschutz, Saarland,
Germany (permission numbers: 29/2016 and 14/2018).
2.2 | Morris water maze
The Morris water maze test, consisting of a 6-day training phase and a
1-day probe trial, was used to assess the cognitive function of
APP/PS1-transgenic mice and their wild-type littermates, as previ-
ously described (Qin et al., 2016; Schnöder et al., 2020). During train-
ing phase, latency time, distance, and velocity were recorded with
Ethovision video tracking equipment and software (Noldus Informa-
tion Technology, Wageningen, the Netherlands). During the probe
trial, the platform was removed and we measured the latency of first
visit to the location of original platform, the frequency of crossing in
that location, and the time spent in the platform area.
2.3 | Tissue collection and isolation of blood
vessels
Animals were euthanized at 9 months of age by inhalation of iso-
fluorane. Mice were then perfused with ice-cold PBS, and the brain
was removed and divided. The left hemisphere was immediately fixed
in 4% paraformaldehyde (Sigma-Aldrich Chemie GmbH) in PBS and
embedded in paraffin for immunohistochemistry. For one part of mice,
a 0.5-μm-thick sagittal piece of tissue was cut from the right hemi-
sphere. The cortex and hippocampus were carefully separated and
homogenized in TRIzol (Thermo Fisher Scientific, Darmstadt,
Germany) for RNA isolation. The remainder of the right hemisphere
was snap-frozen in liquid nitrogen and stored at −80C until biochem-
ical analysis.
For the other part of mice, the cortex and hippocampus from right
hemisphere were carefully dissected and brain vessel fragments were
isolated according to the published protocol (Boulay, Saubamea,
Decleves, & Cohen-Salmon, 2015). Briefly, brain tissues were homog-
enized in HEPES-contained Hanks' balanced salt solution (HBSS) and
centrifuged at 4,400g in HEPES-HBSS buffer supplemented with
dextran from Leuconostoc spp. (molecular weight 70,000; Sigma-
Aldrich Chemie GmbH) to delete myelin. The vessel pellet was
re-suspended in HEPES-HBSS buffer supplemented with 1% bovine
serum albumin (Sigma-Aldrich Chemie GmbH) and filtered with 20 μm
-mesh. The blood vessel fragments were collected on the top of filter
and stored at −80C for biochemical analysis.
2.4 | Histological analysis
Serial 30-μm-thick sagittal sections were cut from the paraffin-
embedded hemisphere. For each animal, four sections with an interval
of 10 layers between neighboring sections were examined. Human Aβ
was stained with rabbit anti-human Aβ antibody (clone D12B2; Cell
Signaling Technology Europe, Frankfurt am Main, Germany) and
microglia labeled with rabbit anti-ionized calcium-binding adapter mol-
ecule (Iba)-1 antibody (Wako Chemicals, Neuss, Germany), and visual-
ized with the VectaStain Elite ABC kit (Vector Laboratories,
Burlingame, USA) or fluorescence-conjugated second antibodies. In
the whole hippocampus, volumes of Aβ were estimated with the Cav-
alieri method, and Iba-1-positive cells were counted with Optical Frac-
tionator as described previously (Y. Liu et al., 2014) on a Zeiss
AxioImager.Z2 microscope (Carl Zeiss Microscopy GmbH, Göttingen,
Germany) equipped with a Stereo Investigator system (MBF Biosci-
ence, Williston, ND).
To evaluate the cerebral Aβ deposition, four serial brain sections
from each animal were labeled with methoxy-XO4 (Tocris Bioscience,
Wiesbaden-Nordenstadt, Germany) after deparaffinization. The whole
cortex and hippocampus were imaged with Microlucida (MBF Biosci-
ence) and merged. Fluorescence-labeled areas were measured using
the Image J software (https://imagej.nih.gov/ij/) with fixed thresholds
for all compared animals. The percentage of Aβ coverage in the brain
was calculated.
To detect the deposition of Aβ at blood vessels, brain sections were
co-stained with human Aβ antibody (clone D12B2) and biotin-labeled
Griffonia Simplicifolia Lectin I isolectin B4 (Catalog number: B-1205; Vec-
tor Laboratories, Burlingame, CA), and Alexa488-conjugated anti-rabbit
IgG and Cy3-conjugated streptavidin, respectively (Thermo Fisher Scien-
tific). To identify Gpr43-expressing cells, brain sections from
Gpr43-reporter mice were co-stained with rabbit anti-RFP antibody
(Catalog number: 600-401-379; Rockland Immunochemicals, Limerick,
PA) and mouse anti-Tmem119 antibody (clone: 195H4; Synaptic Sys-
tems GmbH, Göttingen, Germany), which were followed by incubation
with Alexa488 or Cy3-conjugated second antibodies (Thermo Fisher
Scientific).
The relationship between microglia and Aβ deposits was investi-
gated as we did in a previous study (Hao et al., 2011). Serial brain sec-
tions were stained with Iba-1 antibody (Wako Chemicals) and
Alexa546-conjugated anti-rabbit IgG (Thermo Fisher Scientific), and
then co-stained with methoxy-XO4 (Bio-Techne GmbH). Under Zeiss
microscopy with 40× objective, Aβ deposits were imaged with green
fluorescence filter. Thereafter, Z-stack serial scanning from −10 to
+10 μm was performed under both green and orange fluorescence
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filters. From each section, more than 10 randomly chosen areas were
analyzed. The total number (>200) of Iba-1-positive cells co-localizing
with Aβ deposits were counted. The area of Aβ was measured with
Image J and used for the adjudgment of microglial cell number.
To quantify vasculature in the brain, our established protocol was
used (Decker et al., 2018; Quan et al., 2020). Four serial paraffin-
embedded sections per mouse with 300 μm of distance in between
were deparaffinized, heated at 80C in citrate buffer (10 mM, pH = 6)
for 1 hr and digested with Digest-All 3 (Pepsin) (Thermo Fisher Scien-
tific) for 20 min. Thereafter, brain sections were stained with rabbit
anti-collagen IV polyclonal antibody (Catalog number: ab6586; Abcam,
Cambridge, UK) and Alexa488-conjugated goat anti-rabbit IgG (Thermo
Fisher Scientific). After being mounted, the whole hippocampus was
imaged with Microlucida (MBF Bioscience). The length, branching
points, and density of collagen type IV staining-positive blood vessels
were analyzed with a free software, AngioTool (http://angiotool.nci.nih.
gov; Zudaire, Gambardella, Kurcz, & Vermeren, 2011). The mean diame-
ter of blood vessels was calculated by dividing total area of blood ves-
sels with the total length of vessels. The parameters of analysis for all
compared samples were kept constant. The length and branching points
were adjusted with brain area of interest.
2.5 | Western blot analysis
Frozen mouse brains were homogenized on ice in 5× radio-
immunoprecipitation assay buffer (RIPA buffer; 50 mM Tris [pH 8.0],
150 mM NaCl, 0.1% SDS, 0.5% sodiumdeoxy-cholate, 1% NP-40, and
5 mM EDTA) supplemented with protease inhibitor cocktail (Sigma-
Aldrich Chemie GmbH), followed by centrifugation at 16,000g for 30 min
at 4C to collect the supernatants. Isolated blood vessels were directly
lysed in 2 × SDS-PAGE sample loading buffer containing 4% SDS and
sonicated before loading. The protein levels of synaptic proteins:
Munc18-1 protein mammalian homolog (Munc18-1), synaptosome-
associated protein 25 (SNAP-25), postsynaptic density protein 95 (PSD-
95) and synaptophysin were detected with rabbit polyclonal antibodies
(Catalog numbers: 13414, 3926, and 2507, respectively; Cell Signaling
Technology) and mouse monoclonal antibody (clone SY38; Abcam). In
the same sample, β-actin was detected as a loading control using rabbit
monoclonal antibody (clone: 13E5; Cell Signaling Technology). For the
detection of proteins in cerebral capillaries, rabbit monoclonal antibodies
against platelet-derived growth factor receptor β (PDGFRβ), CD13/APN,
ABCB1, and vinculin (clone: 28E1, D6V1W, E1Y7S, and E1E9V respec-
tively; Cell Signaling Technology) and rabbit polyclonal antibodies against
LRP1 and α-tubulin (Catalog numbers: 64099 and 2144, respectively;
Cell Signaling Technology), tight junction protein 1 (TJP1; Catalog num-
bers: NBP1-85047; Novus Biologicals, Wiesbaden-Nordenstadt, Ger-
many), Claudin-5 (Thermo Fisher Scientific) and aquaporin 4 (AQP4;
Proteintech Europe, Manchester, United Kingdom) were used. Western
blots were visualized via the ECL method (PerkinElmer LAS GmbH,
Rodgau, Germany). Densitometric analysis of bands was performed with
the Image J software. For each sample, the protein level was calculated
as a ratio of target protein/β-actin, α-tubulin or vinculin.
For detection of Aβ oligomers, the proteins in the brain homoge-
nate or in the isolated blood vessels were separated by 10–20%
precasted Tris-Tricine gels (Anamed Elektrophorese GmbH, Groß-
Bieberau/Rodau, Germany). For Western blot, anti-human Aβ mouse
monoclonal antibody (clone W0-2; Merck Chemicals GmbH, Darm-
stadt, Germany), anti-β-actin, or anti-α-tubulin antibodies (Cell Signal-
ing Technology) were used.
2.6 | β- and γ-secretase activity assays
Membrane components were purified from the brain homogenate of
9-month-old APP/PS1-transgenic mice with and without heterozy-
gous deletion of myd88 gene and β- and γ-secretase activity were
measured by incubating the crude membrane fraction with secretase-
specific FRET substrates according to our established methods (Hao
et al., 2011; Xie et al., 2013).
2.7 | Positive selection of CD11b-positive
microglia in the adult mouse brain
To determine the gene expression in microglia, CD11b-positive cells were
isolated from the entire cerebrum of 9-month-old APP/PS1-transgenic
mice with our established protocol (Y. Liu et al., 2014). A single-cell sus-
pension was prepared with Neural Tissue Dissociation Kit (papain-based)
(Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany) and selected
with MicroBeads-conjugated CD11b antibody (Miltenyi Biotec). Lysis
buffer was immediately added to CD11b-positive cells for isolation of total
RNA with RNeasy Plus Mini Kit (Qiagen, Hilden, Germany).
2.8 | Quantitative PCR for analysis of gene
transcripts
Total RNA was isolated from mouse brains or selected CD11b-
positive cells and reverse-transcribed. Gene transcripts were quanti-
fied with our established protocol (Y. Liu et al., 2014) using Taqman
gene expression assays of mouse tumor necrosis factor (tnf-α), interleu-
kin-1β (il-1β), inducible nitric oxide synthase (inos), chemokine (C–C
motif) ligand 2 (ccl-2), il-10, chitinase-like 3 (chi3l3), mannose receptor C
type 1 (mrc1), insulin-like growth factor (igf)-1, triggering receptor
expressed on myeloid cells 2 (trem2), apoe, CX3C chemokine receptor 1
(cx3cr1), purinergic receptor P2Y12 (p2ry12), C-type lectin domain family
7 member A (clec7a), lipoproteinlipase (lpl), transforming growth factor β
receptor 1 (tgfbr1), integrin α X (itgax), neprilysin, insulin-degrading
enzyme (ide), and glyceraldehyde 3-phosphate dehydrogenase (gapdh)
(Thermo Fisher Scientific). The transcription of osteopontin (opn), vas-
cular endothelial growth factor (vegf ), and peptidyl-prolyl cis-trans isom-
erase A (ppia) genes in CD11b-positive cells was evaluated using the
SYBR green binding technique with the following pairs of primers:
opn, 50-CAGCCATGAGTCAAGTCAGC-30 and 50-TGTGGCTGT
GAAACTTGTGG-30; vegf, 50-CCCTTCGTCCTCTCCTTACC-30 and
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50-AGGAAGGGTAAGCCACTCAC-30; and ppia, 50-AGCATACAGGT
CCTGGCATCTTGT-30 and 50-CAAAGACCACATGCTTGCCATCCA-30.
The primer sequences for detecting the transcripts of various recep-
tors of free fatty acids were listed in the legend of Figure S1.
2.9 | Pericyte culture and treatments
Human primary brain vascular pericytes (HBPC) were immortalized by
infecting cells with tsSV40T lentiviral particles (Umehara et al., 2018).
The selected immortalized HBPC clone 37 (hereafter referred to as
HBPC/ci37) was used for our study. HBPC/ci37 cells were cultured at
33C with 5% CO2/95% air in pericyte medium (Catalog: # 1201;
Sciencell Research Laboratories, Carlsbad, CA) containing 2% (v/v)
fetal bovine serum, 1% (w/v) pericyte growth factors, and penicillin–
streptomycin. Culture flasks and plates were treated with Collagen
Coating Solution (Catalog: # 125-50; Sigma-Aldrich). HBPC/ci37 cells
were used at 40–60 passages in this study.
To investigate the effects of inflammatory activation on expression
of LRP1, PDGFRβ, and CD13, pericytes were cultured in 12-well plate at
5.0 × 105 cells/well. Before experiments, the culture medium was rep-
laced with serum-free pericyte medium and cells were cultured at 37C
for 3 days to facilitate the cell differentiation (Umehara et al., 2018).
Thereafter, pericytes were treated with recombinant human IL-1β
(Catalog: # 201-LB; R&D Systems, Wiesbaden-Nordenstadt, Germany)
at 0, 5, 10 and 50 ng/ml for 24 hr, or for 8 days with and without with-
drawal of IL-1β for the last 3 days. At the end of experiments, cultured
cells were lysed in RIPA buffer supplemented with protease inhibitor
cocktail. Protein levels of LRP1, PDGFRβ, and CD13 were detected with
quantitative Western blot as described in Section 2.5.
2.10 | Statistical analysis
Data were presented as mean ± SEM. For multiple comparisons, we
used one-way or two-way ANOVA followed by Bonferroni, Tukey, or
Dunnett T3 post hoc test (dependent on the result of Levene's test to
determine the equality of variances). Two independent-samples Stu-
dents t-test was used to compare means for two groups of cases. All
statistical analyses were performed with GraphPad Prism 8 version
8.0.2. for Windows (GraphPad Software, San Diego, CA). Statistical
significance was set at p <.05.
3 | RESULTS
3.1 | Haploinsufficient expression of MyD88 in
microglia protects neurons and improves cognitive
function of APP/PS1-transgenic mice
To investigate effects of microglial MyD88 on AD pathogenesis, we mated
APP/PS1-transgenicmicewithMyD88fl/fl mice andCx3Cr1-CreERT2mice.
Littermate mice with APPtgMyd88fl/wtCre+/− and APPtgMyd88fl/wtCre−/−
of genotypes were injected with tamoxifen at 6 months of age. Tamoxifen-
induced gene recombination should delete one allele of myd88 gene in
>93%microglia but not in other brain cells (Goldmann et al., 2013). Tamoxi-
fen injection also knocks out loxP site-flanked myd88 gene in peripheral
Cx3Cr1-positive myeloid cells; however, normal MyD88-expressing mye-
loid cells produced from the bone marrow should replace these
MyD88-deficient cellswithin 1month (Goldmann et al., 2013). By detecting
myd88 gene transcripts in CD11b-positive brain cells from 9-month-old
APPtgMyd88fl/wtCre+/− (MyD88het) and APPtgMyd88fl/wtCre−/−
(MyD88wt) mice, we observed that the transcriptional level of myd88 in
microglia of MyD88het mice was only 11.4% of that in MyD88wt mice
(myd88/gapdh: 0.178 ± 0.054 [wt] and 0.020 ± 0.004 [het]; t test, p = .044;
n = 3 per group), which was in accordance with a previous observation that
heterozygous knockout ofmyd88 gene reducedmyd88 transcripts by 66%
in the whole brain of APP-transgenic mice (Michaud et al., 2011). As a con-
trol, transcriptional levels ofmyd88 (myd88/gapdh) in CD11b-positive blood
cells were 0.100 ± 0.023 and 0.123 ± 0.025, in MyD88het and MyD88wt
mice, respectively (t test, p = .518; n = 4 per group), which indicated that
peripheral myeloid cells had been replenished by bone marrow-produced
cells expressingMyD88 at a normal level.
We used the Morris water maze test to examine cognitive function
of mice. During the acquisition phase, 9-month-old non-APP-transgenic
(APPwt) littermate mice with or without haploinsufficiency of microglial
MyD88 (APPwtMyd88fl/wtCre+/− and APPwtMyd88fl/wtCre−/−) showed
no significant differences in either swimming time or swimming distance
before climbing onto the escape platform (Figure 1a,b; two-way
ANOVA, p >.05). Compared to APPwtMyd88fl/wtCre−/− littermates,
9-month-old APPtgMyd88fl/wtCre−/− mice with normal MyD88 expres-
sion spent significantly more time (Figure 1a; two-way ANOVA, p <.05)
and traveled longer distances (Figure 1b; two-way ANOVA, p <.05) to
reach the escape platform. Interestingly, APPtgMyd88fl/wtCre+/− mice
with the heterozygous deletion of microglial MyD88 performed signifi-
cantly better than their APPtgMyd88fl/wtCre−/− littermates in searching
and finding the platform after 3 days of training (Figure 1a,b; two-way
ANOVA, p <.05). The swimming velocity did not differ between
MyD88-deficient and wild-type APP-transgenic mice or for the same
mice on different training dates (data not shown).
Twenty-four hours after the end of training phase, the escape plat-
form was removed and a 5-min probe trial was performed to test the
memory of mice. Compared to APPwtMyd88fl/wtCre−/− littermates,
APPtgMyd88fl/wtCre−/− mice crossed the region where the platform had
been located with significantly less frequency, and remained for a signifi-
cantly longer time in their first visit to the original platform region during
the total 5-min probe trial (Figure 1c,d; one-way ANOVA followed by
post-hoc test, p <.05). Interestingly, when compared to APPtgMyd88fl/
wtCre−/− mice, APPtgMyd88fl/wtCre+/− mice were able to cross the
region more frequently and reach the original platform region in less
time (Figure 1c,d; one-way ANOVA followed by post-hoc test, p <.05).
We observed differences in neither parameter analyzed in the probe
trial between APPwtMyd88fl/wtCre+/− and APPwtMyd88fl/wtCre−/− litter-
mate mice (Figure 1c,d; one-way ANOVA, p >.05).
In our previous study, we have observed that overexpression
of APP/PS1 decreases protein levels of synaptic proteins
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(Schnöder et al., 2020). We further used Western blot analysis to
quantify the levels of four synaptic structure proteins: Munc18-1, syn-
aptophysin, SNAP-25, and PSD-95 in the brain homogenate of
9-month-old APPtg littermate mice with different expression of MyD88.
As shown in Figure 1e–g, protein levels of synaptophysin, and SNAP-25
in APPtgMyd88fl/wtCre+/− mice were significantly higher than levels of
these proteins derived from APPtgMyd88fl/wtCre−/− littermate mice
(t test, p <.05). Haploinsufficient expression of MyD88 in microglia
tended to increase the protein level of PSD-95 in the brain as compared
with MyD88-wildtype AD mice (Figure 1i; t test, p = .096).
3.2 | Haploinsufficient expression of MyD88 in
microglia reduces Aβ load in the brain parenchyma and
blood vessels of APP/PS1-transgenic mice
After observing that heterozygous deletion of MyD88 in microglia
attenuated cognitive deficits of APPtg mice but not of APPwt litter-
mates, we analyzed the effects of microglial MyD88 on Aβ load in the
APPtg mice, as Aβ is the key molecule leading to neurodegeneration in
AD (Mucke & Selkoe, 2012). We stained brain sections from
APPtgMyd88fl/wtCre+/− and APPtgMyd88fl/wtCre−/− mice with
methoxy-XO4, which specifically recognizes β-sheet secondary struc-
ture of Aβ. We observed that haploinsufficiency of microglial MyD88
significantly reduced the area of methoxy-XO4 staining-positive Aβ
plaques in both hippocampus and cortex of APP/PS1-transgenic mice
(Figure 2a,b; t test, p <.05). We then used standard immunohistological
and stereological Cavalierimethods to evaluate Aβ volume, adjusted rel-
ative to the volume of analyzed tissues, in the hippocampus of
9-month-old APPtgMyd88fl/wtCre+/− and APPtgMyd88fl/wtCre−/− mice.
The volume of 7.67% ± 0.71% of APPtgMyD88fl/wtCre+/− mice was sig-
nificantly lower than that of APPtgMyD88fl/wtCre−/− mice (10.83% ±
0.56%; Figure 2c,d; t test, p <.05).
To measure the amount of oligomeric Aβ in brain tissues, quanti-
tative Western blot was performed as we did in previous studies
(Schnöder et al., 2016, 2020). We observed that the protein level of
dimeric but not monomeric Aβ in 9-month-old APPtgMyD88fl/wtCre+/
− mice was significantly lower than that in APPtgMyD88fl/wtCre−/− lit-
termates (Figure 2e,f; t test, p <.05). Dimer has been considered as a
toxic species of Aβ aggregates (Shankar et al., 2008).
Aβ is deposited not only in the brain parenchyma, but also at
blood vessels (Stakos et al., 2020). Blood circulation contributes to Aβ
clearance (Roberts et al., 2014). APP/PS1-transgenic mice used in our
study were not a typical animal model for amyloid angiopathy; how-
ever, we observed an impairment of vasculature in their brain (Decker
et al., 2018). Thus, we examined the potential localization of Aβ at
blood vessels. We did observe that Aβ deposited in and around cere-
bral blood vessels of APP/PS1-transgenic mice (Figure 2h). To quan-
tify the blood vessels-associated Aβ, we isolated capillaries from the
brain homogenate and detected Aβ in the tissue lysate. Interestingly,
the protein level of dimeric Aβ in APPtgMyD88fl/wtCre+/− mice was
also significantly lower than that in APPtgMyD88fl/wtCre−/− littermate
mice (Figure 2i,j; t test, p <.05). As a negative experimental control,
F IGURE 1 Haploinsufficiency of microglial MyD88 improves
cognitive function and attenuates AD-associated loss of synaptic proteins
in APP/PS1-transgenic mice. During the training phase of the water maze
test, 9-month-old APP-transgenic mice (APPtg) spent more time and
traveled longer distances to reach the escape platform than did their non-
APP-transgenic littermates (APPwt). Compared to mice with normal
expression of MyD88 (wt), heterozygous deletion of MyD88 in microglia
(het) significantly reduced the traveling time and distance of APPtg mice
but not of APPwt mice (a,b; two-way ANOVA followed by Bonferroni
post hoc test; n ≥5 per group). In the probe trial, APPtg mice crossed the
region where the platform was previously located with significantly less
frequency during the total 5-min experiment, and spent significantly
longer time in the first visit to the platform region; heterozygous deletion
of MyD88 in microglia recovered these APP expression-induced
cognitive impairments (c,d; one-way ANOVA followed by Bonferroni post
hoc test). Western blotting was used to detect the amount of synaptic
structure proteins, Munc18-1, SNAP25, synaptophysin, and PSD-95 in
the brain homogenate of 9-month-old APPtg mice (e–i).
Haploinsufficiency of microglial MyD88 was associated with higher
protein levels of synaptophysin and SNAP25 (t test; n ≥5 per group)
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oligomeric Aβ species could not be detected in capillaries isolated
from non-APP transgenic mice (Figure 2i).
In APPtgMyd88fl/wtCre+/− mice, one allele of cx3cr1 gene is replaced
by the insertion of Cre-encoding sequence (Yona et al., 2013). To investi-
gate the potential effects of heterozygous knockout of cx3cr1 gene in
APPtgMyd88fl/wtCre+/− mice, we created APP/PS1-transgenic control
mice with APPtgGpr43fl/flCre+/− and APPtgGpr43fl/flCre−/− of genotypes,
in which gpr43, instead of myd88 gene was loxP site-flanked. By
detecting gpr43 gene transcripts in CD11b-positive brain cells and
staining RFP in the brain tissue of Gpr43-reporter mice, we observed that
F IGURE 2 Haploinsufficiency of
microglial MyD88 reduces cerebral Aβ load in
APP/PS1-transgenic mice. Six-month-old
APPtgMyD88fl/wtCre+/− (MyD88 het) and
APPtgMyD88fl/wtCre−/− (MyD88 wt) were
injected with tamoxifen and analyzed by
9 months of age for Aβ load in the brain. Brain
sections were first stained with methoxy-XO4
and imaged with Microlucida (a). The area of
Aβ plaques were quantified and adjusted by
the area of analyzed brain tissue (b). Brain
sections were further stained with human
Aβ-specific antibodies (c) and the volume of
immune reactive Aβ deposits in hippocampus
were estimated with stereological Cavalieri
method and adjusted by the volume of
analyzed tissues (d). Heterozygous deletion of
microglial MyD88 significantly decreases Aβ
deposits in the brain (b,d; t test; n ≥9 per each
group). The brains derived from 9-month-old
microglial MyD88-het and wt APP-transgenic
mice were also homogenized in RIPA buffer
for Western blot analysis of soluble Aβ
(monomeric and dimeric) (e). To demonstrate
the relationship between blood vessels and
Aβ, brain sections were co-stained Aβ
antibodies and isolectin B4. Some Aβ deposits
are located in and around the vessels (h;
marked with arrow heads). Thereafter, micro
blood vessels were isolated from 9-month-old
MyD88-het and wt APP-transgenic mice and
homogenized in RIPA buffer for Western blot
analysis of monomeric and dimeric Aβ.
Haploinsufficiency of MyD88 significantly
reduces dimeric Aβ in the whole brain
homogenate and isolated cerebral blood
vessels of APP-transgenic mice (f,g,j,k; t test;
n ≥6 per each group) [Color figure can be
viewed at wileyonlinelibrary.com]
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there was no expression (or expression at a very low level) of Gpr43 in
microglia (see Figure S1a,b), which corroborated a previous observation
(Erny et al., 2015). As Gpr43 was absent in microglia of both
APPtgGpr43fl/flCre+/− and APPtgGpr43fl/flCre−/− mice, the phenotypical
difference between these two groups of mice was caused by
haploinsufficiency of Cx3Cr1. Surprisingly, with immunohistochemical
methods, we did not detect changes of cerebral Aβ deposits in
APPtgGpr43fl/flCre+/− mice compared with APPtgGpr43fl/flCre−/− litter-
mate mice (see Figure S1c,d; t test, p >.05).
3.3 | Haploinsufficient expression of MyD88 in
microglia inhibits pro-inflammatory activation in APP/
PS1-transgenic mouse brain
Microglial inflammatory activation contributes to neuronal degeneration
(Heneka et al., 2015). We observed that the number of Iba-1-
immunoreactive cells (representing microglia) in the hippocampus was sig-
nificantly fewer in 9-month-old microglial MyD88-haploinsufficient
APP/PS1-transgenic mice than in MyD88-wild-type APP/PS1-transgenic
littermates (APPtgMyd88fl/wtCre+/− mice, 1.64 ± 0.16 × 104 cells/mm3
vs. APPtgMyd88fl/wtCre−/− mice, 2.60 ± 0.29 × 104 cells/mm3; t test,
p <.05; Figure 3a,b). Haploinsufficiency of MyD88 in microglia did not
change the number of Iba-1-positive cells in 9-month-old non-APP trans-
genic mice (Figure 3b; t test, p >.05).
We further measured transcripts of M1-inflammatory genes (tnf-
α, il-1β, inos, and ccl-2) and M2-inflammatory genes (il-10, chi3l3, and
mrc1) in brains of 9-month-old APPtgMyd88fl/wtCre+/− and
APPtgMyd88fl/wtCre−/− mice. As shown in Figure 3c,d,
haploinsufficient expression of MyD88 in microglia significantly
reduced cerebral tnf-a and il-1β transcripts in APP-transgenic mice
compared to MyD88-wildtype AD littermate mice (t test, p <.05).
However, the transcription of other genes tested was not changed by
MyD88 deficiency in microglia (Figure 3e–i).
F IGURE 3 Haploinsufficiency of microglial MyD88 inhibits inflammatory activation in the brain of APP-transgenic mice. Six-month-old
APPtgMyD88fl/wtCre+/− (MyD88 het) and APPtgMyD88fl/wtCre−/− (MyD88 wt) mice were injected with tamoxifen and analyzed at 9 months of age for
neuroinflammation. Microglia were stained with fluorescence-conjugated Iba-1 antibodies (a) and counted with the stereological probe, Optical
Fractionator. Haploinsufficiency of MyD88 reduced Iba-1-positive cells in 9-month-old APP-transgenic (APPtg) mice, but not in 9-month-old APP-wild-
type (APPwt) mice (b; one-way ANOVA followed by Bonferroni post hoc test; n ≥6 per group for APPtg mice and = 3 per group for APPwt mice). The
inflammatory activation in brain was further analyzed with real-time PCR to detect transcripts of both pro- and anti-inflammatory genes (c–i). Transcription
of pro-inflammatory genes, tnf-α and il-1β, was reduced by heterozygous deletion of MyD88 in 9-old APPtg mice (c and d; t test; n ≥9 per group) [Color
figure can be viewed at wileyonlinelibrary.com]
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In additional experiments, we also detected transcripts of inflamma-
tory genes (tnf-α, il-1β, ccl-2, and il-10) in the brains of 9-month-old
APPtgGpr43fl/flCre+/− and APPtgGpr43fl/flCre−/− mice, which were
injected with tamoxifen by 6 months of age. As shown in Figure S1e–h,
heterozygous deletion of cx3cr1 gene did not change the inflammatory
gene transcription in APPtgGpr43fl/flCre+/− mice as compared with
Cx3Cr1-wild-type APPtgGpr43fl/flCre−/− mice (t test, p >.05).
3.4 | Haploinsufficient expression of MyD88
suppresses pro-inflammatory activation in microglia
but enhances microglial responses to Aβ in APP/PS1-
transgenic mice
Recently, disease-associated microglia (DAM) phenotype was defined
after comparing microglial transcriptome between APP/PS1-transgenic
F IGURE 4 Haploinsufficiency of MyD88 inhibits pro-inflammatory activation in microglia and enhances microglial responses to Aβ deposits in the
brain of APP-transgenic mice. Microglia were selected with magnetic beads-conjugated CD11b antibodies from 9-month-old tamoxifen-injected
APPtgMyD88fl/wtCre+/− (MyD88 het) and APPtgMyD88fl/wtCre−/− (MyD88 wt) mice. Transcription of signature genes associated with
neurodegenerative diseases were detected with real-time PCR. MyD88 deficiency significantly decreases transcripts of tnf-α, il-1β, chi3l3, and cx3cr1
genes (a,b,e,i; t test; n ≥5 per group). Iba-1 was also co-stained with methoxy-XO4, which recognizes aggregated Aβ (o). Haploinsufficiency of MyD88
significantly increases recruitment of microglia toward Aβ deposits (p; t test; n ≥ 6 per each group) [Color figure can be viewed at wileyonlinelibrary.com]
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F IGURE 5 Haploinsufficiency of microglial MyD88 increases cerebral vasculature of APP/PS1-transgenic mice. The brains of 9-month-old
tamoxifen-injected APPtgMyD88fl/wtCre+/− (MyD88 het) and APPtgMyD88fl/wtCre−/− (MyD88 wt) mice were stained for collagen type IV. The
blood vessels in the hippocampus were thresholded and skeletonized. The skeleton representation of vasculature is shown in red and branching
points of blood vessels are in blue (a) The total length, density and branching points of blood vessels were calculated and adjusted by area of
analysis (b–d; t test, n ≥11 per group). The mean diameter of blood vessels was calculated by dividing area of total blood vessels with total length
of vessels (e). In order to analyze the relationship between vasculature and microglia, brain sections were co-stained with isolectin B4 (in red) and
Iba-1 antibodies (in green) (f). Haploinsufficiency of MyD88 in microglia significantly increased the distribution of microglia around blood vessels
(g; one-way ANOVA followed by Bonferroni post hoc test; n = 6 per group for APP-transgenic [tg] mice and = 3 per group for APP-wildtype [wt]
mice). Moreover, CD11b-positive brain cells were quantified for the transcription of pro-angiogenic genes. The transcription of opn and igf-1
genes, but not of vegf gene was significantly up-regulated by MyD88 deficiency (h,i; t test, n ≥5 per group). In order to evaluate the integrity of
BBB, isolated brain capillaries were detected for TJP1, Claudin-5, and AQP4 with quantitative Western blot (k). Haploinsufficiency of MyD88 in
microglia did not significantly change the expression levels of all proteins tested (l–n; t test, p >.05, n ≥8 per group) [Color figure can be viewed at
wileyonlinelibrary.com]
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F IGURE 6 Haploinsufficiency of microglial MyD88 increases LRP1 in cerebral micro-vessels of APP/PS1-transgenic mice and IL-1β treatment
decreases LRP1 in cultured pericytes. Micro blood vessels were isolated from the brains of 9-month-old APPtgMyD88fl/wtCre+/− (MyD88 het) and
APPtgMyD88fl/wtCre−/− (MyD88 wt) mice, which were injected with tamoxifen 3 months ago. Protein levels of LRP1, ABCB1, PDGFRβ, and CD13 were
determined with quantitative Western blot (a–e). Haploinsufficiency of MyD88 in microglia significantly elevates LRP1 protein level but not for other
proteins tested, compared with MyD88-wildtype APP/PS1-transgenic mice (b; t test, n ≥6 per group). Immortalized pericytes from human cerebral
capillaries were cultured and treated with IL-1β at various concentrations for 24 hr (f–i) or for 8 days with and without withdrawal of IL-1β during the
last 3 days (j–m). At the end of experiments, cell lysates were prepared from IL-1β-treated pericytes and detected for LRP1, PDGFRβ, and CD13 with
quantitative Western blot. One-way ANOVA comparing levels of each tested protein at different concentrations of IL-1β shows that: (1) IL-1β
treatments significantly decreases LRP1, but increases PDGFRβ and CD13 in a concentration-dependent manner after a 24-hr treatment (g–i; p values
are shown in the figure); (2) IL-1β treatments significantly decreases LRP1 in a concentration-dependent manner after a 8-day treatment (k; p <.001);
and (3) IL-1β treatments does not significantly changes protein levels of PDGFRβ and CD13 after a 8-day treatment (l,m). Two-way ANOVA comparing
protein levels of LRP1, PDGFRβ, or CD13 with and without withdrawal of IL-1β in the last 3 days of experiments shows that withdraw of IL-1β recovers
expression of LRP1 (k; p = .004), but not for PDGFRβ and CD13 (l,m). t test was used to analyze the difference of protein levels in cells treated with IL-
1β at 50 ng/ml shows that withdrawal of IL-1β significantly recovers expression of LRP1, PDGFRβ, and CD13 (k–m; **: p <.01). n = 3 or 4 per group
[Color figure can be viewed at wileyonlinelibrary.com]
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and wild-type mice. This signature is characterized by an induction of
pro-inflammatory genes (including il-1β, ccl2, and itgax), and a suppres-
sion of homeostatic genes (e.g., cx3cr1, p2ry12, tmem119, tgfbr1, sall1,
and csf1r). APOE and TREM2 are two signaling proteins essential for
DAM development (Keren-Shaul et al., 2017; Krasemann et al., 2017).
We quantified the transcription of several DAM signature genes to
characterize the effects of MyD88 on microglial activation. We
observed that haploinsufficiency of MyD88 significantly decreased tran-
scripts of pro-inflammatory genes, tnf-α and il-1β (Figure 4a,b; t test,
p <.05), and also reduced the transcription of anti-inflammatory gene
chi3l3 (Figure 4e; t test, p <.05) and homeostatic gene cx3cr1 (Figure 4i;
t test, p <.05), as compared with MyD88-wildtype microglia.
In order to investigate the relationship between microglia and Aβ
deposits, we co-stained brain sections of 9-month-old AD mice with
Iba-1-specific antibodies and methoxy-XO4. There were significantly
more microglia surrounding Aβ deposits in APPtgMyd88fl/wtCre+/−
mice (6.21 ± 0.47 × 102 cells/mm2) than in APPtgMyd88fl/wtCre−/−
mice (2.68 ± 0.24 × 102 cells/mm2; Figure 4o,p; t test, p <.001), which
agrees with our previous observation in MyD88-deficient bone mar-
row chimeric APP-transgenic mice (Hao et al., 2011).
3.5 | Haploinsufficient expression of MyD88 in
microglia increases cerebral vasculature in APP/PS1-
transgenic mice
We observed that cerebral microvasculature is reduced in
APP/PS1-transgenic mice (Decker et al., 2018). In this study, we asked
whether haploinsufficiency of microglial MyD88 changed the vascula-
ture in AD mouse brain. We stained brains of 9-month-old
APPtgMyd88fl/wtCre+/− and APPtgMyd88fl/wtCre−/− mice with collagen
type IV-specific antibodies, skeletonized and quantified the immunore-
active blood vessels (Figure 5a). As shown in Figure 5b–d, MyD88 defi-
ciency in microglia significantly increased the total length, vessel density
and branching points of micro-blood vessels (t test, p <.05), but did not
change the mean diameter of blood vessels (Figure 5e; t test, p >.05).
As resident microglia serve pro-angiogenic effects in the brain
(Brandenburg et al., 2016; Jiang et al., 2020; Mastorakos et al., 2021),
we co-stained Iba-1 and isolectin B4 on brain sections of 9-month-old
APPtgMyd88fl/wtCre+/− and APPtgMyd88fl/wtCre−/− mice and counted
microglia with and without contact with blood vessels in CA1 area of
the hippocampus (Figure 5f). We observed that haploinsufficiency of
MyD88 significantly increased the distribution of microglia to blood
vessels (Figure 5g; one-way ANOVA followed by post-hoc test,
p <.05). Furthermore, we quantified gene transcription of pro-
angiogenic genes in CD11b-positive brain cells. As shown in
Figure 5h–j, MyD88 deficiency significantly up-regulated the tran-
scription of opn and igf-1 genes (t test, p <.05).
To evaluate the integrity of BBB in AD mice, we quantified TJP1,
Claudin-5 and AQP4 in blood vessels isolated from 9-month-old
APPtgMyd88fl/wtCre+/− and APPtgMyd88fl/wtCre−/− mice. As shown in
Figure 5k–n, haploinsufficiency of MyD88 in microglia did not signifi-
cantly alter the protein levels of all proteins tested (t test, p >.05).
3.6 | Haploinsufficient expression of MyD88 in
microglia increases LRP1 in cerebral capillaries of
APP/PS1-transgenic mice
LRP1 mediates Aβ efflux and local clearance by pericytes at BBB (Ma
et al., 2018; Shinohara et al., 2017). We isolated micro-vessels from
brains of 9-month-old APPtgMyd88fl/wtCre+/− and APPtgMyd88fl/
wtCre−/− mice and observed that haploinsufficiency of MyD88 in
microglia significantly increased protein levels of LRP1, but not ABCB1
in APP/PS1-transgenic mice, as compared with MyD88-wildtype AD
mice (Figure 6a–c; t test, p <.05). The protein levels of pericyte markers,
PDGFRβ, and CD13, were not changed by microglial deficiency of
MyD88 (Figure 6d,e; t test, p >.05). In isolated blood vessels from non-
APP-transgenic control mice (APPwtMyd88fl/wtCre+/− and
APPwtMyd88fl/wtCre−/−), haploinsufficiency of MyD88 in microglia did
not alter the protein levels of all molecules examined (data not shown).
To examine the effects of inflammatory activation on LRP1
expression, we treated cultured pericytes with recombinant IL-1β
either for 24 hr or for 8 days. As shown in Figure 6f,g,j,k, both short-
and long-term treatments of IL-1β significantly decreased the protein
levels of LRP1 in a dose-dependent manner (one-way ANOVA,
p <.05). In the 8-day treatment experiment, withdrawal of IL-1β for
the last 3 days restored expression of LRP1 in cultured pericytes
(Figure 6j,k; two-way ANOVA, p <.05). The short-term treatment of
IL-1β markedly increased expression of PDGFRβ and CD13, which
corroborates our recent finding (Quan et al., 2020) (Figure 6f,h,i; one-
way ANOVA, p <.05). The long-term treatment of IL-1β only at a high
concentration (e.g., 50 ng/ml) tended to decrease the expression of
PDGFRβ and CD13; however, it was not statistically significant
(shown in Figure 6l,m with solid lines; one-way ANOVA, p >.05). The
withdrawal of IL-1β recovered the expression of PDGFRβ and CD13
in cultured pericytes after treatment of IL-1β at 50 ng/ml (Figure 6l,m;
t test comparing cells with and without treatment of IL-1β at
50 ng/ml, p <.05).
3.7 | Haploinsufficient expression of MyD88 in
microglia decreases β- and γ-secretase activity but
does not affect neprilysin and ide gene transcription in
the brain of APP/PS1-transgenic mice
Cerebral Aβ level is determined by Aβ generation and clearance. We
continued to ask whether MyD88-deficient microglia regulated Aβ
production. Using our established protocols (Hao et al., 2011; Xie
et al., 2013), we detected the activity of β- and γ-secretases in brains
of 9-month-old APPtgMyd88fl/wtCre+/− and APPtgMyd88fl/wtCre−/−
mice. Interestingly, the activity of both enzymes was significantly
lower in the brain of APPtgMyd88fl/wtCre+/− mice than in MyD88-wil-
dtype APPtgMyd88fl/wtCre−/− littermates (Figure 7a,b; two-way
ANOVA, p <.05).
To further investigate the clearance of Aβ, we quantified gene
transcripts of Aβ-degrading enzymes, neprilysin, and ide (Leissring
et al., 2003). There were no changes in the transcription of neprilysin
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and ide genes in both brain tissues and microglia from 9-month-old
APPtgMyd88fl/wtCre+/− mice compared with APPtgMyd88fl/wtCre−/−
mice (Figure 7c–f; t test, p >.05), suggesting that haploinsufficiency of
MyD88 in microglia does not affect Aβ catabolism.
4 | DISCUSSION
Microglial activation has been extensively investigated in AD brain
(Heneka et al., 2015), but microglial effects on Aβ pathology and neu-
ronal degeneration remain inconclusive. In this study, we deleted one
allele of myd88 gene specifically in microglia in APP/PS1-transgenic
mice by 6 months. Notably, by 9 months of age these animals showed
attenuation both in the total number of microglia and in the transcrip-
tion levels of pro-inflammatory genes (e.g., tnf-α and il-1β) within the
whole brain and individual microglia, correlating with decreased Aβ
load and improved cognitive function. Interestingly,
MyD88-haploinsufficient microglia might prevent APP/PS1
overexpression-induced changes of cerebral vasculature and LRP1
expression at BBB.
The regulating effects of innate immune signaling on the role of
microglia in AD pathogenesis are highly heterogenous. For example,
TREM2 is essential for microglial response to Aβ in the brain (Ulland
et al., 2017). One group reported that TREM2 deficiency in APP-
transgenic mice increases hippocampal Aβ burden and accelerates
neuron loss (Y. Wang et al., 2015), while another group showed that
TREM2 deletion reduces cerebral Aβ accumulation (Jay et al., 2015).
Subsequent work suggested that TREM2 may have a protective effect
at the early disease stage through phagocytic clearance of Aβ, but dis-
play a pathogenic effect at the later disease stage by triggering neuro-
toxic inflammatory responses (Jay et al., 2017; Parhizkar et al., 2019).
In our studies, we reduced MyD88 expression in microglia or in bone
marrow cells of APP-transgenic mice after noticeable Aβ had already
developed in the brain, which decreases cerebral Aβ load and protects
neurons (Hao et al., 2011). In the experiments by other groups,
MyD88 expression was manipulated in APP-transgenic mice before
the birth (by cross-breeding) or at 2 months of age (by bone marrow
reconstruction) before Aβ deposits appeared in the brain. With such
an experimental setting, MyD88-deficient microglia promote Aβ accu-
mulation in the brain and accelerate spatial memory deficits (Michaud
et al., 2011, 2012). Thus, the pathogenic role of innate immune mole-
cules in microglia is shaped by the evolving cellular environment and
should be analyzed dynamically during AD progression.
MyD88, as a common signaling adaptor for most TLRs and IL-1
receptor, plays an essential role in the innate immune response
(O'Neill, Golenbock, & Bowie, 2013). It is not surprising that the het-
erozygous deletion of myd88 gene inhibits the inflammatory activa-
tion of microglia in APP/PS1-transgenic mice. MyD88 deficiency
F IGURE 7 Haploinsufficiency of MyD88 in microglia decreases β- and γ-secretase activity, but does not affect the transcription of neprilysin
and ide genes in the brain of APP/PS1-transgenic mice. The brains of 9-month-old tamoxifen-injected APPtgMyD88fl/wtCre+/− (MyD88 het) and
APPtgMyD88fl/wtCre−/− (MyD88 wt) mice were used to prepare membrane components and RNA isolation. β- and γ-secretase activity was
measured by incubating membrane components with fluorogenic β- and γ-secretase substrates, respectively (a,b, two-way ANOVA comparing
MyD88 wt and het mice; n = 4 per group). The transcripts of neprilysin and ide genes in the brain tissue (c,e) and isolated microglia (d,f) were
measured with real-time PCR, which showed that transcription of neprilysin and ide genes was not changed by the haploinsufficiency of MyD88
in microglia (t test; n ≥5 per group)
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might reduce the generation of new microglia, as we previously
observed that deletion of IKKβ, a signaling molecule downstream to
MyD88, decreases proliferating microglia in APP-transgenic mice
(Y. Liu et al., 2014). It is unlikely that MyD88 deficiency induces
microglial cell death in APP/PS1-transgenic mice, as blocking MyD88
signaling inhibits TLR4 activation-induced microglial apoptosis (Jung
et al., 2005), while TLR4 is a receptor mediating microglial response to
Aβ challenge (Walter et al., 2007). Interestingly, we observed that
MyD88 deficiency promotes clustering of microglia around Aβ
deposits as we observed in MyD88-deficient bone marrow chimeric
AD mice (Hao et al., 2011). As deficiency of MyD88, IKK2, or TLR2
increases Aβ internalization by cultured microglia or macrophages
(Hao et al., 2011; S. Liu et al., 2012; Y. Liu et al., 2014), the
haploinsufficiency of MyD88 perhaps enhances microglial clearance
of Aβ in AD brain. The relationship between microglial clustering and
Aβ reduction in APP-transgenic mice has been described in many
studies. For example, deficiency of TREM2 blocks microglial recruit-
ment to Aβ, which is correlated with cerebral Aβ accumulation
(Y. Wang et al., 2015). Administration of TREM2 agonist antibodies
increases Aβ-associated microglia, which decreases Aβ in the brain
(Fassler, Rappaport, Cuno, & George, 2021; Price et al., 2020;
S. Wang et al., 2020). However, the molecular mechanisms, which
mediate the migration of microglia toward Aβ and the following Aβ
internalization, remain unclear.
The haploinsufficiency of MyD88 strongly decreases the tran-
scription of cx3cr1, chi3l3, tnf-α, and il-1β genes in microglia of our
APP/PS1-transgenic mice. Cx3Cr1 expression is up-regulated in the
brain of AD patients or animal models (Gonzalez-Prieto et al., 2021).
Deficiency of Cx3Cr1 decreases cerebral Aβ in various APP-transgenic
mice (Hickman, Allison, Coleman, Kingery-Gallagher, & El
Khoury, 2019; Lee et al., 2010; Z. Liu, Condello, Schain, Harb, &
Grutzendler, 2010). Homozygous knockout of cx3cr1 gene was also
observed to increase Aβ deposits-associated microglia and microglial
phagocytosis of Aβ (Z. Liu et al., 2010). However, it should be noted that
the reduction of cx3cr1 transcription in our APPtgMyd88fl/wtCre+/− mice
might be caused by the replacement of endogenous cx3cr1 gene by Cre-
encoding sequence (Yona et al., 2013). To address the question whether
Cx3Cr1 haploinsufficiency in APPtgMyd88fl/wtCre+/− mice affects amy-
loidosis, we created APPtgGpr43fl/flCre+/− and APPtgGpr43fl/flCre−/−
mice, in which gpr43 instead of myd88 gene was loxP site-flanked. As
Gpr43 is not expressed in microglia in both APPtgGpr43fl/flCre+/− and
APPtgGpr43fl/flCre−/− mice (Erny et al., 2015), any changes in
APPtgGpr43fl/flCre+/− mice relative to APPtgGpr43fl/flCre−/− littermates
should be due to the haploinsufficiency of Cx3Cr1. Our experiments rev-
ealed that the haploinsufficiency of Cx3Cr1 alters neither Aβ deposition
nor transcription of inflammatory genes (e.g., tnf-α, il-1β, ccl-2, and il-10)
in the brain of our APP/PS1-transgenic mice. Thus, the pathological
improvement in APPtgMyd88fl/wtCre+/− mice is a result from the
haploinsufficiency of MyD88 instead of Cx3Cr1 deficiency in microglia.
Chi3l3 is a known marker for alternative activation of microglia
and macrophages. Its transcription is also elevated in APP-transgenic
mouse brain (Colton et al., 2006). However, the pathogenic function
of microglial Chi3l3 in AD mice is indeed unknown. Our serial studies
revealed that neuroinflammation and Aβ level are often simulta-
neously attenuated in the brain of APP-transgenic mice (Hao
et al., 2011; S. Liu et al., 2012; Y. Liu et al., 2014). As pro-inflammatory
activation inhibits phagocytosis of cultured microglia (Koenigsknecht-
Talboo & Landreth, 2005), inhibition of proinflammatory activation in
microglia might help Aβ clearance in AD brain. However, systemic
injection of TLR4 or TLR9 agonist induces both pro- and anti-
inflammatory activation and decreases Aβ in the brain of AD mice
(Michaud et al., 2013; Scholtzova et al., 2014). Thus, how inflamma-
tory activation regulates Aβ clearance in the brain is still an unan-
swered question.
There is growing evidence showing that microvascular circulation
is damaged in AD brain; for example, capillary density and cerebral
blood flow decrease, while BBB permeability increases (Watanabe
et al., 2020). Our previous study showed that the blood flow goes
down in correlation with a reduced vasculature in the hippocampus of
APP-transgenic mice (Decker et al., 2018). Aβ-activated perivascular
macrophages injure the neurovascular coupling through producing
reactive oxygen species (Park et al., 2017). However, microglia were
observed to serve pro-angiogenic effects in brains with glioma, ische-
mia, or direct vascular injury (Brandenburg et al., 2016; Jiang
et al., 2020; Mastorakos et al., 2021). Transcription of opn, vegf and
igf1 genes in microglia is associated with angiogenesis (Jiang
et al., 2020). Our study showed that haploinsufficiency of MyD88 in
microglia increases cerebral vasculature, and distribution of microglia
around blood vessels. MyD88 deficiency also up-regulates the tran-
scription of opn and igf-1 genes in microglia. As OPN enhances VEGF
expression in endothelial cells (Dai et al., 2009) and IGF-1 drives the
tissue repairment, including angiogenesis, in the brain (Vannella &
Wynn, 2017), MyD88-haploinsufficient microglia might prevent vas-
cular impairment in AD brain. However, a postmortem tissue study
showed a higher density of capillaries in the brain of AD patients
(Fernandez-Klett et al., 2020). Tg4510 tau-transgenic mice display
increased capillaries, but with atypical and spiraling morphologies, and
reduced luminal diameter of blood vessels (Bennett et al., 2018). Thus,
more studies, especially functional analysis of the effects of microglia
on the microvascular circulation in AD, are required.
BBB breakdown is an early biomarker of AD (Nation et al., 2019).
APOE4 variant was recently linked to the loss of BBB integrity before
the cognitive deficit (Montagne et al., 2020). The cerebrovascular
leakage of 100 nm nanoparticles was observed in APP-transgenic
mice (Tanifum, Starosolski, Fowler, Jankowsky, & Annapragada, 2014).
However, the effects of microglia on BBB integrity in AD brain remain
unclear. In a mouse model of systemic lupus erythematosus, microglial
activation around blood vessels protects BBB at the initial phase by
expressing tight-junction protein Claudin-5, and impairs BBB by
phagocytosing astrocytic end-feet after the inflammation is sustained
(Haruwaka et al., 2019). In our study, we did not observe altered pro-
tein levels of TJP1, Claudin-5, and AQP-4 in microglial
MyD88-haploinsufficient AD mice, although we were not able to
exclude small damages in BBB integrity.
LRP1 contributes to Aβ clearance at BBB through mediating Aβ
efflux and pericyte internalization of Aβ (Ma et al., 2018; Shinohara
2000 QUAN ET AL.
et al., 2017). Deletion of LRP1 in endothelial cells accumulate Aβ in
APP-transgenic mouse brain (Storck et al., 2016). LRP1 expression
decreases in brain capillaries with aging and in AD (Shibata et al., 2000).
Pro-inflammatory cytokines, such as IL-1β, IL-6, and TNF-α, down-
regulate LRP1 in cultured microvascular endothelial cells (Hsu,
Rodriguez-Ortiz, Zumkehr, & Kitazawa, 2021). Our experiments showed
that LRP1 expression is decreased by IL-1β treatments in cultured peri-
cytes. In APP/PS1-transgenic mice, MyD88-haploinsufficient microglia
elevates LRP1 protein level in cerebral capillaries, which might be due to
the inflammatory inhibition. It was supported by another observation
that inflammatory activation in the brain by systemic administration of
lipopolysaccharide decreases Aβ efflux at BBB (Erickson, Hansen, &
Banks, 2012). PDGFRβ and CD13 are two receptors on pericytes and
essential for the survival and integration of pericytes in blood vessels
(Lindahl, Johansson, Leveen, & Betsholtz, 1997; Rangel et al., 2007). The
expression of PDGFRβ and CD13 appeared to be resistant to inflamma-
tory regulation, as haploinsufficiency of MyD88 did not change their
protein levels in AD mice. Their expression in cultured pericytes was not
altered, either, by IL-1β at the concentrations sufficient for the down-
regulation of LRP1 expression. There was a recent study showing that
the density of pericytes is reserved during AD pathogenesis (Fernandez-
Klett et al., 2020).
Aβ is produced after serial digestions of APP by β-(BACE1) and
γ-secretases (Haass, Kaether, Thinakaran, & Sisodia, 2012). The
expression of BACE1 in neurons is up-regulated by inflammatory acti-
vation (He et al., 2007; Sastre et al., 2006). Our studies showed that
p38α-MAPK deficiency promotes BACE1 degradation in neurons
(Schnöder et al., 2016). Recently, inflammatory cytokines, such as
interferon-γ and α, were shown to induce the expression of
interferon-induced transmembrane protein 3 in neurons and astro-
cytes, which binds to γ-secretase and increases its activity (Hur
et al., 2020). Thus, haploinsufficient expression of MyD88 in microglia
in our APP/PS1-transgenic mice decreases neuroinflammation, and
inhibits β- and γ-secretase activity in the brain, which might serve as
another mechanism decreasing Aβ level in AD mice.
In summary, haploinsufficient expression of MyD88 in microglia
at a late disease stage slows down the cognitive decline of
APP/PS1-transgenic mice. MyD88 deficiency inhibits pro-
inflammatory activation of microglia, but enhances microglial response
to Aβ, which subsequently attenuates Aβ load in the brain.
Haploinsufficiency of MyD88 might enhance pro-angiogenic effects
of microglia, and prevent the loss of LRP1-mediated Aβ clearance at
BBB in AD. However, the effects of microglia on the structure and
function of micro-vessels in AD are far from being understood. To
answer these questions will be a focus of our following studies.
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